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1. Introduction 
The prevalence of ischemic heart disease and acute myocardial infarction (AMI) has increased 
to alarming rates in the United States and the western world (Roger et al., 2011). Patients who 
survive the initial AMI suffer ischemic cardiomyopathy (ICM) which is often complicated by 
high mortality and poor overall prognosis (Braunwald et al., 2000; McMurray et al., 2005). 
Despite significant advances in medical therapy and revascularization strategies, the prognosis 
of patients with AMI and ischemic cardiomyopathy remains dismal (Levy D et al., 2002; Roger 
VL et al., 2004). The last decade has demonstrated significant progress and rapid translation of 
myocardial regenerative therapies particularly those utilizing stem cells isolated from adult 
tissues (Abdel-Latif et al., 2007).  
Studies examining the potential therapeutic use of bone marrow (BM)-derived cells in 
myocardial regeneration have overshadowed the growing evidence of innate cardiac 
reparatory mechanisms. Several studies have demonstrated the capability of 
cardiomyocytes to replenish through poorly understood innate mechanisms. Follow up of 
cardiac transplantation patients have demonstrated continuous replenishment of 
cardiomyocytes by recipient’s derived cells through poorly understood mechanisms (Quaini 
et al., 2002). There is growing evidence that BM-derived cells are responsible, at least in part, 
for organ chimerism including cardiomyocyte chimerism (de Weger et al., 2008; Deb et al., 
2003). Animal studies have confirmed this to be a dynamic process responding to significant 
injury such as myocardial infarction and peaks in the peri-infarct zone (Hsieh et al., 2007). 
Although this process appears to be robust enough to achieve the renewal of approximately 
50% of all cardiomyocytes in the normal life span, very little is known about its 
underpinnings (Bergmann et al., 2009).  
www.intechopen.com
 Advances in Hematopoietic Stem Cell Research 
 
426 
Complex innate reparatory mechanisms are initiated by myocardial ischemia interacting 
with different elements of the immune system, the infarcted myocardium and bone marrow 
stem cells, culminating in BM-stem and progenitor cells’ (SPCs) mobilization as we and 
others have demonstrated (Abdel-Latif et al., 2010; Walter et al., 2007; Wojakowski et al., 
2009). However, very little is known about the mechanisms and clinical significance of this 
mobilization. Animal studies show that mobilized BM-derived cells (BMCs) repopulate the 
infarct border, however the significance of this mobilization is unclear given the low rate of 
their differentiation into cardiomyocytes (Fukuhara et al., 2005).  
2. Isolation and functional characteristics of BM-derived pluripotent stem 
cells 
The bone marrow acts as a reservoir for a heterogeneous pool of tissue-committed and 
non-committed stem cells. These populations contain progenitors that aid in the 
chimerism and cellular turnover of different organs as well as very rare populations of 
pluripotent and non-committed stem cells. The old dogma that adult tissues lack 
pluripotent stem cells (PSCs) has been continuously challenged during the last decade 
through multiple studies that isolated PSCs from adult humans’ and animals’ tissues. 
These populations were distinguished based on their morphology with small cell size, 
large nucleus demonstrating euchromatin and large nucleus to cytoplasm ratio. 
Furthermore, cell surface markers as well as nuclear transcription factors, such as 
SSEA1/4, Oct4 and Nanog, have been deployed. 
Very small embryonic like stem cells (VSELs) represent a rare yet pluripotent population 
of adult stem cells. They have been initially described by Dr. Ratajczak’s group in the 
murine BM based on their expression of Sca1 (murine stem cell marker) and lack of 
expression of CD45 (pan–leukocytic marker) and differentiated lineage (Lin) markers 
(Kucia et al., 2006; Zuba-Surma et al., 2008). Following their isolation from murine tissues, 
VSELs were subsequently isolated from human BM, umbilical cord blood (CB) and 
peripheral blood based on the lack of expression of Lin/CD45 and the expression of the 
stem cell markers CD133, CXCR4 and CD34. Figure 1 illustrates the flow cytometry 
protocol for identifying and isolating VSELs from murine and human samples. VSELs 
were further characterized using a multi-dimensional approach comprising molecular, 
protein and cell imaging techniques to confirm their pluripotent features (Zuba-Surma et 
al. 2008). VSELs are morphologically similar to embryonic stem cells demonstrating small 
diameter compared to more committed progenitors/stem cells with large nucleus 
containing open-type chromatin surrounded with thin rim of cytoplasm and multiple 
mitochondria (Zuba-Surma et al. 2008).  
VSELs exhibit multiple embryonic and pluripotent surface and nuclear embryonic markers 
such as Oct4, SSEA1/4, Nanog, and Rex1. In vivo and in vitro studies have demonstrated 
the capability of VSELs to differentiate into multiple cell lines across germ lines including 
cardiomyocytes (Kucia et al. 2006). 
The bone marrow harbors other multi- and pluri-potent stem cell populations such as the 
mesenchymal stem cells (MSC) (Hattan et al., 2005; Kawada et al., 2004), multipotent adult 
progenitor cells (MAPC) (Jiang et al., 2002), and marrow-isolated multilineage inducible cells 
(MIAMI) (D'Ippolito et al., 2004). Similar populations with cardiac differentiation potential 
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have been also isolated from skeletal muscle and other tissues (Abdel-Latif et al., 2008a). 
However, it is conceivable that different investigators have isolated, using different 
methods, the same or very similar populations and named them differently. It is also 
possible that these populations at least in part contain VSELs which might explain their 
pluripotent potential. 
 
Panel A: Gating strategy for isolating human cord blood (CB)-derived VSELs. Morphology of total CB-
derived nucleated cells is shown on dot-plot representing FSC and SSC parameters related to cell size 
and granularity/ complexity, respectively. All objects larger than 2m are enclosed in region R1 and 
further visualized on histogram showing the expression of markers of mature hematopoietic cells 
(lineage markers; Lin). Cells not expressing differentiated hematopoietic markers (Lin- in region R2) are 
then analyzed for CD34 and CD45 expression. VSELs are identified as CD45-/Lin-/CD34+ cells (region 
R3), while hematopoietic stem cells (HSCs) as CD45+/Lin-/CD34+ cells (region R4).  
Panel B: Sorting of murine bone marrow (BM)-derived VSELs. Morphology of total murine BM-derived 
nucleated cells is shown on dot-plot presenting FSC and SSC parameters and all objects in range of 2-
10m in diameter are included in region R1. Lymphocytic cells including stem cell fraction is further 
analyzed for Sca-1 and differentiated hematopoietic lineages markers (Lin) expression and only Sca-
1+/Lin- cells are included in region R2. Cells from this region are further seperated based on CD45 
expression. Murine VSELs are distinguished as CD45-/Lin-/Sca-1+ cells (region R3), while HSCs as 
CD45+/Lin-/Sca-1+ cells (region R4).  
Fig. 1. Strategy for flow cytometric analysis of human and murine Very Small Embryonic-
Like and hematopoietic stem cells. Briefly, BM is flushed from the femurs and tibias. 
Nucleated cells are isolated by lysis of red blood cells and cells are then gated on based on 
the cell size (>2 m). Of note, lysis is preferred for isolating VSELs rather than Ficoll 
gradient that we have shown to lose some of the VSELs due to their small size.  
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3. BM-derived pluripotent stem cells are mobilized in the peripheral 
circulation following myocardial ischemia in animal models and humans 
Myocardial ischemia, particularly large myocardial infarction, produce multiple stimuli 
include various chemokines, cytokines, kinins, bioactive lipids and members of the 
complement cascade, that lead to the mobilization and subsequent homing of BMSPCs. 
Indeed, several reports have confirmed that mobilization of stem cells originating from the 
BM occurs in response to myocardial ischemic injury (Grundmann et al., 2007; Kucia et al., 
2004b; Leone et al., 2005; Massa et al., 2005; Shintani et al., 2001; Wojakowski et al., 2006) and 
heart failure (Valgimigli et al., 2004). Similar observations were noted in patients with acute 
neurological ischemia (Paczkowska et al., 2005) and patients with extensive skin burn 
(Drukala et al., 2011).  
Stimuli responsible for the mobilization and homing of BMSCs in the setting of myocardial 
ischemia show similarities and differences with those involved in hematopoietic stem cells 
(HSCs) homing to the BM. The role of stromal cell derived factor (SDF-1) and its receptor 
(CXCR4) axis in the retention of hematopoietic stem/progenitor cells (HSPCs) in bone 
marrow is undisputed (Kucia et al., 2005; Lapidot et al., 2002), however, its role in the 
mobilization and homing of BM-SPCs to a highly proteolytic microenvironment, such as the 
ischemic/infarcted myocardium, is somewhat less certain. Studies have demonstrated that 
multiple members of the metalloproteinases (MMP) family, such as MMP2, MMP9 and 
MMP13, are upreagulated in the myocardium following infarction (Peterson et al., 2000). 
The elevated levels of the MMPs contribute to the degradation of chemokines such as SDF-1 
and the byproduct of this degradation acts as an inhibitor the sole SDF-1 receptor, CXCR4 
(McQuibban et al., 2001; McQuibban et al., 2002). In support of this hypothesis, Agrawal et al 
demonstrated that the conditional deletion of CXCR4 in cardiomyocytes did not influence 
the recovery of left ventricular (LV) function, reduce the scar size or alter the homing of 
MSCs to the myocardium following myocardial infarction (Agarwal et al., 2010). Thus, there 
is growing evidence that other mechanisms beside the SDF-1/CXCR4 axis are contributing 
to the mobilization and homing of BM-SPCs in AMI and other conditions (Jalili et al., 2010; 
Ratajczak et al., 2010). These data suggest an important interplay between the complement 
cascade, the immune system, cathelicidins, low levels of SDF-1, and sphingosine-1 
phosphate (S1P) and other bioactive lipids in the mobilization and homing of HSPCs. Our 
preliminary data suggest that these complex interactions might be involved in the 
mobilization of BM-SPCs in acute myocardial ischemia as well (unpublished data). 
Clinically, pharmacological modulators of S1P receptors are already approved by the FDA 
and can be utilized to enhance BM-SPC mobilization in the setting of ischemic heart disease. 
Similarly, modulation of the complement cascade can be also utilized in this process similar 
to their role in the mobilization of HSPCs. 
The first evidence for the mobilization of CD34+ mononuclear cells in AMI was 
demonstrated by Shintani et al (Shintani et al. 2001). The authors demonstrated successful in 
vitro differentiation of circulating BM-SPCs into endothelial cells that expressed CD31, VE-
cadherin and the kinase insert domain receptor (KDR) (Shintani, et al. 2001). Leone et al 
demonstrated that the levels of circulating CD34+ cells in the setting of AMI were higher 
when compared to patients with mild chronic stable angina and healthy controls. The 
magnitude of CD34+ cell mobilization correlated with the recovery of regional and global 
LV function recovery as well as other functional LV parameters (Leone et al. 2005). Similarly, 
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Wojakowski et al demonstrated the mobilization of multiple BM-SPCs populations in 
patients with AMI and found significant correlation between the number of circulating 
CD34+ cells and plasma SDF-1 levels (Wojakowski et al., 2004). In their following 
publication, the authors demonstrated the correlation between circulating BM-SPCs and 
ejection fraction at baseline and lower brain natriuretic peptide (BNP) levels (Wojakowski et 
al. 2006). Interestingly, the mobilization of BM-SPCs is reduced by the successful 
revascularization of the culprit vessel in acute STEMI (Müller-Ehmsen et al., 2005). However, 
the majority of the above mentioned studies have focused on the mobilization of partially 
committed stem cells such as HSPCs and endothelial progenitor cells (EPCs).  
We and others have demonstrated the mobilization of pluripotent stem cells (PSCs) 
including VSELs in the setting of myocardial ischemia (Abdel-Latif et al. 2010; Wojakowski 
et al. 2009). The number of circulating VSELs was highest in patients with ST-elevation 
myocardial infarction (STEMI), particularly in the early phases following the injury, when 
compared to patients with lesser degrees of ischemia such as non STEMI (NSTEMI) and 
those with chronic ischemic heart disease (Abdel-Latif et al. 2010). The mobilization of PSCs 
appears to be related to the extent of myocardial ischemia and the degree of myocardial 
damage. Moreover, the ability of patients to mobilize PSCs in the peripheral circulation in 
response to AMI decreases with age, reduced global LV ejection fraction (LVEF) and 
diabetes supporting the notion of an age/comorbidity related decline in the regenerative 
capacity (Abdel-Latif, et al. 2010; Wojakowski, et al. 2009). Indeed, animal models confirm 
the reduction of number as well as pluripotent features of BM-derived VSELs with age 
(Zuba-Surma et al. 2008). Similarly, studies have demonstrated the reduction of number as 
well as functional capacity of EPCs in diabetic patients (Fadini et al., 2006).  
The pluripotent features of mobilized VSELs, including the presence of octamer-binding 
transcription factor-4 (Oct4) and stage specific embryonic antigen-4 (SSEA4), were 
confirmed both on the RNA and protein levels. Utilizing the capabilities of the ImageStream 
system, we demonstrated that circulating VSELs during AMI have very similar embryonic 
features similar to their BM and CB counterparts including the small size (7-8 m), large 
nucleus and high nuclear-to-cytoplasm ratio (Figure 2). Furthermore, circulating VSELs 
during AMI express markers of early cardiac and endothelial progenitors that suggest that 
the mobilization is rather specific and that circulating VSELs are destined to aid in the 
myocardial regeneration following injury (Abdel-Latif et al. 2010; Kucia et al. 2004b; 
Wojakowski et al. 2009).  
The above evidence suggest an innate, yet poorly understood, reparatory mechanism that 
culminates in the mobilization of BMSCs including pluripotent and embryonic like stem 
cells in acute myocardial injury. This mobilization correlates with the recovery of LV 
function and other LV functional parameters. Therefore, mobilization of PSCs in myocardial 
ischemia is a relevant and clinically significant process. Future studies aiming at selective 
mobilization of PSCs rather than the non-selective actions of agents such as granulocyte 
colony stimulating factor (G-CSF) may prove beneficial in the field of myocardial 
regeneration. 
Indeed, there is evidence that the mobilization of CXCR4+ cells in the setting of AMI is 
correlated with LVEF recovery as well as myocardial reperfusion when assessed with 
cardiac MRI in humans (Wojakowski, et al. 2006).  
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Fig. 2. Representative ImageStream images of VSEL and hematopoietic stem/ progenitor 
cell (HSPC) circulating in peripheral blood following acute ST-elevation myocardial 
infarction. Cells were stained against: 1)  hematopoietic lineages markers (Lin) and CD45 to 
be detected in one channel (FITC, green), 2) marker of pluripotency Oct4 (PE, yellow) and 3) 
stem cell antigen CD34 (PE-Cy5, cyan). Nuclei are stained with 7-aminoactinomycin D (7-
AAD, red). Scales represents 10 m. VSELs are identified based on the lack of expression of 
both Lin and CD45 markers and positive staining for CD34 antigen and nuclear appearence 
of Oct-4 transcription factor (Upper Panel). HSCs are identified as cell expressing Lin and/ 
or CD45 markers as well as CD34 antigen; however, negative for Oct-4 (Lower Panel). BF: 
Bright field. 
4. Therapeutic mobilization of BM-derived stem cells in myocardial 
regeneration 
Hematologists have used the concept of BM-derived stem cell mobilization using 
pharmacological agents such as G-CSF for a long time. Based on the available clinical 
experience and safety profile of these therapies, pharmacological stem cell mobilization in 
the setting of AMI has gained increasing enthusiasm. Mobilized BM-SPCs are either 
harvested for further transplantation or allowed for spontaneous homing to the infarcted 
myocardium and has demonstrated various degrees of success (Engelmann et al., 2006; Ince 
et al., 2005; Zohlnhöfer et al., 2006). Similar to BMCs transplantation studies, the 
heterogeneous methodologies of the included studies diluted the effect. The overall lack of 
efficacy with G-CSF BMCs mobilization in the setting of acute myocardial infarction is 
somewhat incongruent with the salutary effects of BMCs transplantation in humans and G-
CSF therapy in animal models for myocardial regeneration.  
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The largest study utilizing G-CSF in the setting of acute myocardial infarction was the 
REVIVAL-2 trial that included 114 patients (Zohlnhöfer, et al. 2006). The study randomized 
AMI patients to 10 g/kg of G-CSF vs. placebo and left ventricular functional parameters 
were assessed using cardiac MRI (CMR).  The study demonstrated no significant difference 
in the tested parameters between patients treated with G-CSF or placebo. However, baseline 
characteristics in the study population showed normal or near normal LV function and 
therefore the expected benefit is minimal. Patient selection was a methodological flaw that 
plagued some of the studies that utilized G-CSF. Indeed, with careful examination of the 
available literature, patients with reduced LV function at baseline as well as those treated 
within the first 36 hours following AMI benefited the most (Abdel-Latif et al., 2008b; Achilli 
et al., 2010). On the other hand, safety concerns regarding a potentially increasing evidence 
of instent restenosis (Kang et al., 2004) and recurrent ischemia (Hill et al., 2005) have halted 
subsequent clinical trials. However, it is important to note that these safety concerns were 
not confirmed in large studies (Zohlnhöfer, et al. 2006) or in the cumulative meta-analyses 
(Abdel-Latif et al. 2008b).  
Beyond the methodological flaws encountered in human trials, this lack of efficacy can be 
explained by multiple factors. While G-CSF and similar therapies mobilize a wide array of 
BMSPCs in the peripheral blood, homing factors may not be sufficient to guide them to the 
myocardial infarct zone. Indeed, the homing of c-Kit+ cells to the infarcted myocardium 
improved when G-CSF therapy was combined with local administration of SDF-1 (Askari et 
al., 2003). The myocardial levels of chemoattractants peaks within 24-72 hours following 
injury (Kucia et al., 2004a; Ma et al., 2005; Wang et al., 2006) and therefore delayed therapy in 
some human trials may have missed the homing window to the infarct zone. Similarly, the 
addition of Flt-3 to G-CSF therapy improved outcomes in animal models (Dawn et al., 2008). 
Moreover, different cytokines are known to preferentially mobilize somewhat different 
subsets of BMCs (Hess et al., 2002; Neipp et al., 1998). Future studies investigating the 
characteristics of G-CSF-mobilized cells will be necessary to glean additional mechanistic 
insights in this regard. 
Recently, a combined approach with stem cell mobilization and enhanced homing using 
therapies known to increase local SDF-1 or CXCR4 antagonists have been proposed and is 
currently being tested (Jujo et al., 2010; Zaruba et al., 2009). Going forward, the beneficial 
effects of BM-derived stem cell mobilization may be augmented by selective mobilization of 
undifferentiated BMSCs rather than differentiated inflammatory cells. It is also important to 
remember that some of the G-CSF arbitrated effects can be mediated by its direct effect on 
cardiomyocytes which are known to express G-CSF receptor (Shimoji et al., 2010). G-CSF 
therapy may be inducing the proliferation of cardiomyocytes or the differentiation of 
resident cardiac stem cells. On a similar note, G-CSF therapy upregulates Akt (Ohtsuka et 
al., 2004) and may result in reducing apoptosis of ischemic cardiomyocytes if utilized early 
following the acute event. 
5. BM-derived stem cell transplantation for myocardial repair 
The use of BM-derived cells in myocardial regeneration has moved rapidly from the basic 
research lab to the clinical arena. The results from these studies varied widely probably 
secondary to the heterogeneous methodologies used with an overall marginal benefit with 
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BM-derived cell transplantation compared to placebo. The majority of studies, however, 
utilized unselected populations of BMCs and these studies provide the longest follow-up of 
up to 5 years (Assmus et al., 2010; Schachinger et al., 2009). The underling mechanisms 
leading to the beneficial effect of transplanted BMCs are unclear. The observed benefits of 
BMCs transplantation is out of proportion of the observed rates of newly formed 
cardiomyocytes from BMCs’ origin (Zuba-Surma et al., 2011). Indeed, recent evidence 
suggest a primarily paracrine effect of BM-derived stem cells following their transplantation 
by recruiting and stimulating resident cardiac stem cells (CSCs) (Loffredo et al., 2011). 
Furthermore, human purified CD34+ cells are a source of several growth factors including 
VEGF, cytokines and chemokines that may prevent apoptosis of dying cardiomyocytes and 
promote angiogenesis in damaged myocardium (Majka et al., 2001). Cell membrane derived 
microvesicles or exosomes that are enriched in S1P may contribute to regeneration of 
myocardium and its re-vascularization (Baj-Krzyworzeka et al., 2002). Hence, transplanted 
CD34+ cells may contribute to regeneration of damaged heart by paracrine signals and 
released microvesicles (Ratajczak et al., 2008) and was recently confirmed by others (Sahoo et 
al., 2011).  
Long-term follow-up studies demonstrated ‘catch-up phenomenon’ of the placebo treated 
patients, thus leading to mixed results regarding the sustainability of the BMCs treatment 
benefit (Assmus, et al. 2010; Meyer et al., 2009; Yousef et al., 2009). The benefit of BMCs 
therapy is less robust among patients with chronic ischemic heart disease (IHD) (Assmus et 
al., 2006; Strauer et al., 2010). Similarly, smaller studies have demonstrated the antianginal 
effects of BMCs in patients with non-revascularizable severe coronary artery disease 
(Losordo et al., 2007; Tse et al., 2007). 
Selected BM-derived stem cell subpopulations represent an attractive substrate for cellular 
therapies since they lack the inflammatory cells, which contribute to the ongoing 
inflammatory response at the site of myocardial infarction, contained in the unselected 
BMCs populations. Furthermore, highly purified stem cell populations are more likely to 
induce myocardial regeneration through paracrine effects or by directly differentiating into 
cardiomyocytes. The largest study utilizing selected BM-derived stem cell population is the 
REGENT study which compared selected to non-selected populations of BMCs in patients 
with acute ischemic heart disease and reduced LV function at baseline (Tendera et al., 2009). 
While there were no significant differences between the groups, patients treated with 
selected CD34+/CXCR4+ cells showed trends of improvement in LV function when 
compared to controls. Other studies utilizing primitive populations of BM-SPCs such as 
CD133+ cells have reported improvement of LV function and perfusion (Bartunek et al., 
2005; Stamm et al., 2004). 
Nevertheless and despite the disparity in the methodologies of the conducted studies, the 
overall collective effect of BMCs’ transplantation suggests small yet statistically significant 
benefit in myocardial regeneration (Abdel-Latif, et al. 2007; Martin-Rendon et al., 2008). 
However, these trials have been hampered by their reliance on surrogate endpoints rather 
than patient important endpoints such as mortality, need for repeat revascularization, 
recurrent MI or re-hospitalization for congestive heart failure. While surrogate endpoints are 
important for mechanistic studies, patient-important endpoints are quintessential for a new 
therapy to achieve mainstream status. 
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6. Future directions 
Growing evidence suggest that a multitude of BM-derived stem and pluripotent stem cells 
are mobilized in the peripheral blood following AMI. However, the clinical significance and 
the potential therapeutic use of this mobilization are still not fully understood. Circulating 
PSCs can be used as markers of ischemic injury in humans or as predictors of myocardial 
recovery following large ischemic damage. On the other hand, the therapeutic application of 
VSELs in myocardial regeneration has proven beneficial although the beneficial mechanisms 
remain elusive and are probably mainly paracrine in nature. Given the pluripotent potential 
of VSELs, their transplantation at smaller numbers (10,000 cells per mouse) have proven to 
be more beneficial than larger numbers of the more committed HSPCs (100,000 cells per 
mouse) indicating their greater therapeutic potential (Dawn et al. 2008). Current efforts 
directed at the ex-vivo expansion and priming of VSELs have proven to be a successful 
strategy in animal models and their clinical applications are pending (Dawn et al. 2008; 
Zuba-Surma, et al. 2011). Nuclear reprogramming has opened the door for creating patient-
specific autologous pluripotent stem cells with multiple therapeutic opportunities 
(Takahashi et al., 2006). Further studies are needed to examine the feasibility as well as the 
safety of inducible pluripotent stem cells (iPS) particularly their tumorigenicity and 
immunogenicity before they can be explored in human studies.  
On the biotechnology frontier, multiple modifications of the transplanted cells (priming) 
and the host environment are being tested in humans to improve the efficiency of BM-SPCs’ 
regenerative capacity. Transplanting three dimensional constructs that provide an enriched 
environment for the transplanted and resident stem cells are attractive modifications to the 
currently tested protocols [reviewed in (Mooney et al., 2008)]. Similarly, the concept of 
multiple doses of stem cell to repair the complex process of myocardial remodeling 
following acute myocardial infarction is gaining traction and is very appealing. While the 
field of stem cell regenerative therapy for ischemic heart disease is still in its infancy, the 
accelerated advances in a wide array of biological and biotechnological areas have rapidly 
propelled the field from the bench to clinical applications. 
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